World Journal of Nuclear Medicine最新文献

{"title":"Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions.","authors":"Deya' Aldeen Sweedat, Saad Ruzzeh, Ahmed Saad Abdlkadir, Serin Moghrabi, Marwah Abdulrahman, Akram Al-Ibraheem","doi":"10.1055/s-0046-1820110","DOIUrl":"https://doi.org/10.1055/s-0046-1820110","url":null,"abstract":"<p><p>Gastroenteropancreatic (GEP) malignancies are a major cause of cancer-related mortality, with many patients presenting at advanced stages where curative options are limited. Outcomes remain suboptimal, particularly beyond first-line therapy, highlighting the need for novel approaches. Fibroblast activation protein (FAP)-targeted radioligand therapy (RLT) has emerged as a biologically rational strategy that exploits the stromal compartment of desmoplastic tumors. FAPI PET/CT enables noninvasive assessment of target expression and supports a theranostic framework for patient selection. This review summarizes current clinical evidence on Lutetium-177 ( ¹⁷⁷ Lu)-FAP RLT in GEP cancers, including pancreatic, biliary, gastric, and colorectal malignancies. Available data, largely from small and heterogeneous early-phase studies, demonstrate feasibility and acceptable short-term safety, with hematologic toxicity as the main concern. Objective responses are uncommon; however, disease stabilization and symptomatic benefit have been observed in selected patients. Key limitations include variable tumor retention, heterogeneous selection criteria, and the lack of standardized dosimetry and response assessment. Overall, ¹⁷⁷ Lu-FAP RLT remains investigational but represents a biologically compelling but still clinically unproven biomarker-driven strategy, whose current role is best confined to investigational settings and highly selected patients. Future progress requires optimized ligand design, standardized imaging and dosimetry, and prospective clinical trials to define its clinical role.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"3-11"},"PeriodicalIF":0.9,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WJNM with WARMTH: A Driving Force in Promoting Global Nuclear Medicine.","authors":"Kalevi Kairemo, Akram Al-Ibraheem","doi":"10.1055/s-0046-1820111","DOIUrl":"https://doi.org/10.1055/s-0046-1820111","url":null,"abstract":"","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"1-2"},"PeriodicalIF":0.9,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147820678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET/CT as the Decisive Modality in Distinguishing Clear Cell Sarcoma from Melanoma When Immunohistochemistry Overlaps: A Case Report.","authors":"Efrah Ahmed Ibrahim, Eray Alper","doi":"10.1055/s-0046-1819651","DOIUrl":"https://doi.org/10.1055/s-0046-1819651","url":null,"abstract":"<p><p>Clear cell sarcoma (CCS) and malignant melanoma share overlapping immunohistochemical profiles, particularly SOX10 and HMB45 positivity, making histopathological differentiation challenging. Distinguishing between these entities is clinically essential due to their differing prognoses and therapeutic approaches. This case highlights how fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( ¹⁸ F-FDG PET/CT) contributed decisively to establishing the diagnosis of CCS by following a pathologist-recommended diagnostic algorithm. A 70-year-old male presented with a progressively enlarging left scapular mass. Tru-cut biopsy revealed a malignant neoplasm positive for SOX10 and HMB45, with immunohistochemistry insufficient to differentiate CCS from metastatic melanoma. The pathology report recommended a search for a primary cutaneous melanoma, indicating that in the absence of such a lesion, the diagnosis should favor CCS. Whole-body ¹⁸ F-FDG PET/CT demonstrated extensive metastatic disease involving the lungs, left adrenal gland, T11 vertebra, scapula, and a large presacral mass. Critically, no hypermetabolic cutaneous, mucosal, or nodal lesions suggestive of a primary melanoma were identified. Comprehensive dermatological evaluation was also negative for suspicious melanocytic lesions. Based on the diagnostic algorithm, histopathology, plus exclusion of a primary melanoma, the PET/CT findings supported the diagnosis of metastatic CCS. This case demonstrates that ¹⁸ F-FDG PET/CT can serve as a diagnostic tool when histopathology alone is inconclusive. The absence of a primary melanoma on whole-body ¹⁸ F-FDG PET/CT and clinical examination was the decisive factor favoring CCS over melanoma of unknown primary. This case underscores the limitations of MRI, which often describes CCS as a well-defined, benign-appearing mass, potentially delaying accurate diagnosis.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"93-100"},"PeriodicalIF":0.9,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Performance of ⁶⁸ Ga-FAPI-04 and ¹⁸ F-FDG PET/CT in Ovarian Cancer: Focus on Peritoneal Carcinomatosis.","authors":"Esra Arslan, Göksel Alçin, Nurhan Ergül, Elife Akgün, Ömer Faruk Şahin, Zehranur Tosunoğlu, Ahmet Ertuğrul Öztürk, Tevfik Fikret Çermik","doi":"10.1055/s-0046-1819631","DOIUrl":"https://doi.org/10.1055/s-0046-1819631","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic performance of ⁶⁸ Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) in ovarian cancer compared with ¹⁸ F-FDG PET/CT, focusing on peritoneal carcinomatosis.</p><p><strong>Materials and methods: </strong>Twelve patients with histologically confirmed ovarian cancer underwent both ⁶⁸ Ga-FAPI-04 and ¹⁸ F-FDG PET/CT within 1 week for staging, restaging, or recurrence assessment. SUVmax values of primary tumors, lymph nodes, and peritoneal metastases were compared. Tumor-to-background ratios were calculated, and statistical analyses were performed using nonparametric tests with <i>p</i> <0.05 considered significant.</p><p><strong>Results: </strong>High-grade serous carcinoma was the predominant histology (83.3%). Lymph node metastases were detected in 7/12 patients (58.3%), including distant nodes in 3/12 (25.0%), locoregional nodes in 2/12 (16.7%), and combined disease in 2/12 (16.7%). Peritoneal carcinomatosis was observed in 9/12 patients (75.0%), with significantly higher SUVmax on ⁶⁸ Ga-FAPI-04 compared with ¹⁸ F-FDG (19.17 ± 9.13 vs. 12.41 ± 7.13, <i>p</i>  = 0.016). No significant differences were observed in nodal metastases or distant sites. In 4 of 12 patients (33.3%), ⁶⁸ Ga-FAPI-04 PET/CT identified additional lesions not visualized on ¹⁸ F-FDG PET/CT.</p><p><strong>Conclusion: </strong>⁶⁸ Ga-FAPI-04 PET/CT demonstrated superior peritoneal carcinomatosis detection compared with ¹⁸ F-FDG PET/CT in ovarian cancer. Although derived from a small single-center cohort, these findings are consistent with emerging evidence and highlight the potential role of FAPI imaging in improving staging and management.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"28-33"},"PeriodicalIF":0.9,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical Impact Study of Myocardial Perfusion Imaging Comparing Three Different Cardiac Software Packages at 1-Year Follow-Up.","authors":"Amal Paul, Ashwini Kalshetty, Sandip Basu","doi":"10.1055/s-0046-1819612","DOIUrl":"https://doi.org/10.1055/s-0046-1819612","url":null,"abstract":"<p><strong>Purpose: </strong>Myocardial perfusion imaging (MPI) aids in evaluating the left ventricular function and therefore helps in risk stratification and prognosis. The purpose of this study was to evaluate the clinical impact of three cardiac software packages (Emory Cardiac Toolbox, Cardiogam, and Myovation Evolution) at 1-year follow-up.</p><p><strong>Methods: </strong>This prospective investigation involved 370 patients who underwent myocardial perfusion scintigraphy. Participants were stratified into three groups based on left ventricular ejection fraction determined by two-dimensional echocardiography. Among these, 294 patients were available for follow-up at 1 year. Semiquantitative parameters (summed rest score [SRS], summed stress score [SSS], summed difference score [SDS]) and quantitative parameters (defect extent [DE], transient ischemic dilatation [TID], ejection fraction [EF], end-diastolic volume [EDV], end-systolic volume [ESV], and stroke volume [SV]) derived from each software platform (ECTb, Cgam, and ME) were used to evaluate their diagnostic performance in predicting major adverse cardiac events (MACE) using receiver operating characteristic curve analysis in patients during 1-year follow-up.</p><p><strong>Results: </strong>Among the 294 participants available for follow-up, 6% ( <i>n</i>  = 17) developed MACE at 1 year and 88% ( <i>n</i>  = 15) belonged to the high-risk group. Follow-up analysis indicated that all three software packages could predict 1-year cardiac events with varying cut-off values, sensitivities, and specificities. Cut-off values for SRS (ECTb) was ≥4 (area under the curve [AUC], 0.82), while for Cgam it was ≥11 (AUC 0.8), DE (REST) (ECTb) was ≥6% (AUC 0.82), and Cgam value ≥4.18% (AUC 0.81), EF (REST) was ≤44% (AUC 0.82), ≤68% (AUC 0.84) and ≤35% (AUC 0.83) for ECTb, Cgam, and ME, respectively, EDV (REST) was ≥137 mL for both ECTb (AUC 0.83) and Cgam (AUC 0.85) while for ME it was ≥116 mL (AUC 0.8), ESV (REST) was ≥91 mL (AUC 0.83), ≥55 mL (AUC 0.86) and ≥78 mL (AUC 0.82) for ECTb, Cgam, and ME, respectively.</p><p><strong>Conclusion: </strong>Majority of the MACE occurred in the group with high-risk characteristics. All three software packages demonstrated the ability to predict 1-year cardiac events, albeit with varying parameter cut-off values, sensitivities, and specificities.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"34-41"},"PeriodicalIF":0.9,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 20th International Conference on Radionuclide Therapy (ICRT 2025).","authors":"Savvas Frangos","doi":"10.1055/s-0045-1814142","DOIUrl":"https://doi.org/10.1055/s-0045-1814142","url":null,"abstract":"","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 4","pages":"387-390"},"PeriodicalIF":0.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Non-Invasive Diagnostic Tool for Determining the Subtype of Primary Aldosteronism Using ⁶⁸ Ga Pentixafor PET/CT.","authors":"Ashish K Acharya, Indirani Muthukrishnan Elangovan, Dinesh Kumar Gauthaman, Shelley Simon","doi":"10.1055/s-0045-1814732","DOIUrl":"https://doi.org/10.1055/s-0045-1814732","url":null,"abstract":"<p><strong>Background: </strong>Primary aldosteronism (PA) may present as either unilateral or bilateral disease. Differentiating unilateral forms-unilateral aldosterone- producing adenoma (APA) and unilateral adrenal hyperplasia-from bilateral forms-bilateral APA, bilateral adrenal hyperplasia (BAH)-is critical, as the management strategies differ. Currently, PA subtyping is performed using adrenal vein sampling (AVS) and computed tomography (CT). However, AVS is invasive and technically demanding, and CT has limited accuracy. CXCR4 (CXC chemokine receptor type 4) expression is higher in APAs than in normal adrenal tissue and non-functional tumors. Pentixafor, a CXCR4-specific ligand labelled with ⁶⁸ Ga, has shown potential for PA subtyping.</p><p><strong>Materials and methods: </strong>This prospective observational study included 13 patients with confirmed PA who underwent ⁶⁸ Ga-Pentixafor positron emission tomography/computed tomography (PET/CT) and 13 individuals without PA as controls. Both visual and semi-quantitative analyses were used to classify patients with PA into unilateral or bilateral subtypes.</p><p><strong>Results: </strong>Among the 13 patients with PA, 10 were diagnosed with unilateral primary aldosteronism (UPA) and three with bilateral primary aldosteronism (BPA) based on ⁶⁸ Ga-pentixafor PET/CT. The mean standardized uptake value (SUV) _max , SUV _ratio , and adrenal/liver ratios were significantly higher in patients with UPA than in those with BPA and controls. The 10 patients with UPA underwent adrenalectomy, with histopathological and immunohistochemical analysis confirming the diagnosis. All 10 patients achieved complete biochemical remission post-surgery. The three patients with BPA were started on medical therapy and also achieved biochemical remission.</p><p><strong>Conclusion: </strong>⁶⁸ Ga-Pentixafor PET/CT is a promising non-invasive imaging modality for PA subtyping and may serve as an alternative to AVS in cases where AVS is inconclusive, non-diagnostic, or contraindicated.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"12-18"},"PeriodicalIF":0.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Bilateral Shamblin Type III Carotid Body Tumors and Adrenal Pheochromocytoma with SDHD Mutation: A Rare Presentation, with Multimodality Imaging Findings.","authors":"Roopal Agrawal, Keerti Sitani, Sandip Basu","doi":"10.1055/s-0045-1814731","DOIUrl":"https://doi.org/10.1055/s-0045-1814731","url":null,"abstract":"<p><p>Pheochromocytomas and paragangliomas are relatively rare tumors, with an incidence of approximately 0.6 cases per 100,000 person-years. Moreover, the co-occurrence of these tumors is extremely rare and is often associated with pheochromocytomas/paragangliomas-related pathogenic mutations. We present the case of a 33-year-old female diagnosed with bilateral carotid body paragangliomas and a concurrently detected pheochromocytoma, with metastases to the abdominal lymph nodes and lung. DNA analysis revealed a mutation in the succinate dehydrogenase subunit D gene. The tumors displayed high-grade SSTR expression (Krenning grade 4 uptake) on Gallium-68 [⁶⁸Ga]-DOTA-(Tyr ³ )-octreotate Positron Emission Tomography/Computed Tomography, with no significant tracer concentration on the I-131 MIBG scan. Another notable feature in this case was the visually evident intra- and inter-tumoral metabolic heterogeneity on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography, especially within the multiple carotid paragangliomas. With the adoption of a multimodality diagnostic approach (MRI, FDG PET/CT, SSTR PET/CT, and I-131 MIBG scintigraphy), a holistic theranostic approach was employed with the most rational therapeutic option offered to the patient.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"87-92"},"PeriodicalIF":0.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147820655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Unusual Distant Metastasis in TENIS: Comparative Evaluation of [ ¹⁸ F]FDG and [ ⁶⁸ Ga]-FAPI-04 PET-CT Uptake Patterns at Metastatic Sites.","authors":"Madhava Reddy Mali, Priyanka Verma, Sandip Basu","doi":"10.1055/s-0045-1814419","DOIUrl":"https://doi.org/10.1055/s-0045-1814419","url":null,"abstract":"<p><p>A relatively uncommon occurrence of multiple unusual distant metastasis in a patient with thyroglobulin-elevated negative iodine scintigraphy (TENIS) (subcutis, skeletal muscle, kidney, and pericardium) is presented. A 65-year-old man with papillary thyroid carcinoma post two cycles of radioactive iodine therapy on subsequent follow-up showed elevated serum thyroglobulin (>300 ng/mL) and negative iodine scintigraphy (TENIS). [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for disease restaging revealed extensive metastatic disease involving cervical and mediastinal nodes, bones, liver, subcutis, skeletal muscle, kidney, and pericardium. [68Ga]-fibroblast activation protein inhibitor (FAPI)-04 PET/CT was done to evaluate for fibroblast activation protein (FAP) expression, and the feasibility of targeted radionuclide therapy showed nil to very low FAP expression at the metastatic sites, except for the few cervical and mediastinal nodes, subcutaneous nodule in the left arm, and L3 vertebral lesion. In addition to illustrate the rare presentation in TENIS, this case demonstrates the superiority of [18F]-FDG PET/CT over FAPI PET/CT in this patient. However, FAPI-PET/CT may be used as a theranostic tool for assessing radionuclide therapy prospects in selected cases.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"80-86"},"PeriodicalIF":0.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental Value of Digital PET/MRI over PET/CT in the Assessment of Neoplastic Liver Lesions.","authors":"Pawan Gulabrao Shinkar, Mohana Vamsy, Dileep Kumar, Palak Wadhwa","doi":"10.1055/s-0045-1814145","DOIUrl":"10.1055/s-0045-1814145","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to assess the performance of positron emission tomography/magnetic resonance imaging (PET/MRI) compared with PET/computed tomography (PET/CT) in the clinical management of patients with neoplastic hepatic lesions.</p><p><strong>Materials and methods: </strong>This is a retrospective study and includes a sample size of 15 patients, referred for diagnostic evaluation and staging of neoplastic hepatic lesions. The patients included in this study underwent a simultaneous PET/CT scan on uMI-Vista and a complementary liver PET/MRI scan on uPMR 790. PET/CT and PET/MRI were compared based on the number of detected lesions, the smallest detected lesion diameter, and tumor-to-liver ratio (TLR). The histopathological analysis was considered the standard of reference.</p><p><strong>Results: </strong>PET/MRI reported extra information in 87% (13/15) of patients, and additional lesions were identified in 73% (11/15) of patients. Furthermore, PET/MRI could identify subcentimeter liver lesions and added great value in the evaluation of lesion viability. Overall, 40 additional lesions were detected with PET/MRI in contrast with PET/CT within the given patient cohort. The smallest revealed lesion measured 2 mm in the long-axis diameter, and the average long-axis diameter of small lesions detected by PET/MRI across 15 patients was 3.4 mm with a standard deviation of 1.3 mm. These findings significantly affected the final outcomes in 12 out of 15 patients, leading to modifications in the response assessment category in 5 patients and defined the malignant hepatic lesions on staging/restaging scans (10/15).</p><p><strong>Discussion: </strong>PET/MRI has been found to outperform PET/CT in terms of conspicuity of liver lesions, with better sensitivity and specificity. Overall, coregistered PET and MR images have been shown to outperform PET/CT in the imaging of liver lesions, with better delineation of small lesions as well as reliable localization of lesions to the corresponding liver segment.</p><p><strong>Conclusion: </strong>In addition to a significant decrease in radiation exposure, the PET/MRI combination resulted in higher detection rates and more precise characterization of small malignant liver lesions and tends to be more powerful than PET/CT, which has a direct impact on the patient's diagnosis, staging, and further therapeutic strategies.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 4","pages":"335-345"},"PeriodicalIF":0.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}